Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

C Tomasello, C Baldessari, M Napolitano, G Orsi… - Critical reviews in …, 2018 - Elsevier
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …
被引用次数：62 相关文章

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

C Tomasello, C Baldessari… - Critical reviews in …, 2018 - pubmed.ncbi.nlm.nih.gov
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

C Tomasello, C Baldessari, M Napolitano… - CRITICAL REVIEWS IN …, 2018 - iris.unisr.it
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.

C Tomasello, C Baldessari, M Napolitano… - Critical Reviews in …, 2018 - europepmc.org
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …

[引用][C] Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

C Tomasello, C Baldessari, M Napolitano… - Critical Reviews in …, 2018 - cir.nii.ac.jp
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future
perspectives | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …